Cel
Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented research effort that can only be achieved through collaboration between leading European laboratories and the pharmaceutical industry. To meet this ambition the IMPRiND consortium will synergistically accelerate progress to map and target critical steps in the propagation, proteostatic response and protection against misfolded α-synuclein and tau. Specifically we aim to (1) identify disease-relevant assemblies, imprint their biological properties in vitro and generate homogeneous populations to assay and interfere with their pathogenic effects; (2) develop and miniaturise assays to monitor secretion, uptake, clearance and oligomerisation using bimolecular fluorescence complementation of oligomeric species or transfer of untagged assemblies to fluorescently labelled fibril-naïve cells and measure markers of early proteotoxicity that are suitable for live imaging high content screens; (3) deliver robust validation assays for these molecular events in complex cellular systems with greater functional resemblance to the native milieu of the brain such as iPSC-based and organotypic cultures (4) standardise pathological readouts in animal models for in vivo validation of modifiers, correlate them with novel peripheral or in situ markers using microdialysis to accelerate the assessment of therapeutic interventions and relevance to humans, e.g. by transplantation of human iPSC neurons in animals; (5) assess toxicity and druggability of potential targets. IMPRiND will construct this entire pipeline to examine the prion-like properties of α-synuclein and tau and test their tractability against disease progression.
Dziedzina nauki
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- social sciencessociologygovernancepublic services
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicineneurologyparkinson
- medical and health sciencesclinical medicinetransplantation
Słowa kluczowe
Program(-y)
Zaproszenie do składania wniosków
H2020-JTI-IMI2-2015-07-two-stage
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
RIA - Research and Innovation actionKoordynator
OX1 2JD Oxford
Zjednoczone Królestwo
Zobacz na mapie
Uczestnicy (18)
2500 Valby
Zobacz na mapie
CB2 1TN Cambridge
Zobacz na mapie
SN2 1FL Swindon
Zobacz na mapie
115 27 Athina
Zobacz na mapie
37075 Goettingen
Zobacz na mapie
33000 Bordeaux
Zobacz na mapie
Podmiot prawny inny niż podwykonawca, stowarzyszony lub mający inne powiązania prawne z uczestnikiem. Podmiot realizuje prace na podstawie warunków umowy o grant, dostarcza towary lub świadczy usługi związane z działaniem, jednak nie podpisuje umowy o grant. Podmiot zewnętrzny przestrzega zasad i wymogów dotyczących danego uczestnika wynikających z umowy o grant, dotyczących kwalifikowalności kosztów oraz kontroli wydatków.
75654 Paris
Zobacz na mapie
Zakończenie uczestnictwa
8000 Aarhus C
Zobacz na mapie
75794 Paris
Zobacz na mapie
Zakończenie uczestnictwa
DD1 4HN Dundee
Zobacz na mapie
9052 ZWIJNAARDE - GENT
Zobacz na mapie
53127 Bonn
Zobacz na mapie
2340 Beerse
Zobacz na mapie
4056 Basel
Zobacz na mapie
91190 GIF-SUR-YVETTE
Zobacz na mapie
RG21 4FA Basingstoke
Zobacz na mapie
1025 Saint Sulpice
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
65205 Wiesbaden
Zobacz na mapie